TL;DR
This systematic review and meta-analysis found that while anti-inflammatory therapies don't significantly reduce overall major adverse cardiovascular events in coronary heart disease (CHD) patients, they do show promise in reducing recurrent myocardial infarction and revascularization in patients with stable CHD. Notably, colchicine emerged as a particularly effective agent for primary endpoints in this population, though increased infection risk is a notable side effect across these therapies.
What Problem Does This Paper Address?
Coronary Heart Disease (CHD) remains a leading cause of mortality and morbidity worldwide. Despite advancements in lipid-lowering and antiplatelet therapies, a significant portion of CHD patients still experience residual inflammation, contributing to ongoing cardiovascular risk. This "residual inflammatory risk" (RIR) is thought to drive plaque instability and increase the likelihood of major adverse cardiovascular events (MACEs) like heart attacks and strokes. Anti-inflammatory therapies have been proposed as a way to target this RIR and improve outcomes, but their overall efficacy and specific benefits across different CHD patient populations and agents have been unclear. This paper aims to systematically review and meta-analyze existing randomized controlled trials (RCTs) to provide a comprehensive assessment of the clinical benefits and risks of anti-inflammatory agents for secondary prevention in CHD.
Methods
The researchers conducted a systematic review and meta-analysis of randomized controlled trials (RCTs). They searched major databases (PubMed, Embase, Cochrane Library) for studies published up to June 1, 2021, focusing on anti-inflammatory therapies for CHD. The primary outcomes of interest were a composite of all-cause death, recurrent myocardial infarction, and stroke. Secondary outcomes included components of the primary endpoints and revascularization. They used a random-effects model to pool data from 18 eligible studies involving over 67,000 participants. Subgroup analyses were performed to investigate differences in efficacy between stable CHD and acute coronary syndrome (ACS) patients, and to evaluate specific agents like colchicine.
Datasets
The study did not introduce new datasets. Instead, it synthesized data from 18 previously published randomized controlled trials (RCTs). The characteristics of these included studies, such as the type of anti-inflammatory agent used, patient demographics, and follow-up duration, are detailed in Table 1.
Key Insights and Ideas
- Stable CHD is Key: The most significant benefits of anti-inflammatory therapies were observed in patients with stable CHD, suggesting that targeting inflammation might be more effective when the disease process is less acute and inflammatory.
- Colchicine Shines: Colchicine, a well-established anti-inflammatory drug, showed a promising reduction in primary endpoints, highlighting its potential as a therapeutic strategy for CHD.
- Infection is a Trade-off: A consistent finding across the reviewed studies was an increased risk of infections associated with anti-inflammatory agents, suggesting a need for careful monitoring and potential preventive measures.
- Not a Panacea: While some benefits were identified, the overall picture suggests that anti-inflammatory therapies are not a universal solution for all CHD patients and may not replace established treatments like statins and antiplatelets.
Key Results
The meta-analysis of 18 studies (67,449 participants) revealed that anti-inflammatory agents, when compared to placebo, did not significantly reduce the risk of primary endpoints (all-cause death, recurrent MI, stroke), secondary endpoints, all-cause mortality, cardiac mortality, recurrent myocardial infarction, stroke, or revascularization in the overall CHD population.
However, subgroup analyses yielded more nuanced results:
- Stable CHD Benefits: In patients with stable CHD, anti-inflammatory agents significantly reduced secondary endpoints (OR 0.87, CI 0.77–0.99; P=0.03), recurrent myocardial infarction (OR 0.86, CI 0.78–0.95; P=0.003), and revascularization (OR 0.81, CI 0.70–0.92; P=0.001).
- Stable vs. ACS: Stable CHD patients showed a lower propensity for recurrent myocardial infarction compared to ACS patients when treated with anti-inflammatory agents (P=0.03).
- Colchicine Efficacy: The colchicine subgroup analysis indicated a significant reduction in primary endpoints (OR 0.81, CI 0.70–0.95; P=0.009).
- Adverse Events: Anti-inflammatory agents were associated with a higher risk of infections (OR 1.13, CI 1.03–1.23; P=0.007) but had negligible effects on cancers (OR 0.98, CI 0.90–1.06; P=0.61).
Limitations and Future Work
The authors acknowledge several limitations:
- Follow-up Duration: The mean follow-up duration of the included RCTs was 18.3 months, with a minimum of 30 days. Longer-term outcomes of anti-inflammatory therapy require further investigation.
- Data Availability: Raw patient-level data from all selected studies were not available, necessitating the extraction and reanalysis of study-level data.
- Risk of Bias: Some included studies had incomplete data or potential biases, which could influence the results.
- Revascularization Definition: The definition and indications for revascularization can vary across hospitals, making it a "softest" cardiovascular event and potentially affecting its interpretation.
- Optimal Dosing and Timing: The ideal timing and dosage of anti-inflammatory agents for CHD treatment remain unconfirmed.
- Small Sample Sizes: Several trials had fewer than 300 participants, raising concerns about type I error and small sample size bias.
Future work should focus on large-scale clinical trials to confirm these findings, investigate optimal treatment strategies, and further explore the mechanisms behind the observed benefits and risks. The authors suggest that selective anti-inflammatory therapy, particularly with agents like colchicine in stable CHD patients, holds promise for improving long-term cardiovascular outcomes.
Summary updated